| abstract |
The compounds described have a high affinity for the monoamine transporter and are characterized by one of the two general structures mentioned above. The compounds bind selectively or non-selectively to the monoamine transporter. The compound does not limit attention deficit / hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking cessation, weight loss, obsessive-compulsive disorder, various forms of depression, traumatic encephalopathy, stroke and sleep attacks It is effective in treating various medical indications, including. |